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Background. Carnosinase-1 (CN-1) can be detected in 24 h urine of healthy individuals and patients with type 2 diabetes (T2DM).
We aimed to assess whether urinary CN-1 is also reliably measured in spot urine and investigated its association with renal function
and the albumin/creatinine ratio (ACR). We also assessed associations between the CNDP1 (CTG)n genotype and CN-1
concentrations in serum and urine. Methods. Patients with T2DM (n = 85) and nondiabetic patients with chronic kidney disease
(CKD) (n = 26) stratified by albuminuria (ACR ≤ 300mg/g or ACR > 300mg/g) recruited from the nephrology clinic and
healthy subjects (n = 24) were studied. Results. Urinary CN-1 was more frequently detected and displayed higher concentrations
in patients with ACR > 300mg/g as compared to those with ACR ≤ 300mg/g irrespective of the baseline disease (T2DM:
554 ng/ml [IQR 212-934 ng/ml] vs. 31 ng/ml [IQR 31-63 ng/ml] (p < 0:0001) and nondiabetic CKD: 197 ng/ml [IQR 112-739]
vs. 31 ng/ml [IQR 31-226 ng/ml] (p = 0:015)). A positive correlation between urinary CN-1 and ACR was found (r = 0:68,
p < 0:0001). Multivariate linear regression analysis revealed that ACR and serum CN-1 concentrations but not eGFR or the
CNDP1 genotype are independent predictors of urinary CN-1, explaining 47% of variation of urinary CN-1 concentrations
(R2 = 0:47, p < 0:0001). Conclusion. These results confirm and extend previous findings on urinary CN-1 concentrations,
suggesting that assessment of CN-1 in spot urine is as reliable as in 24 h urine and may indicate that urinary CN-1 in
macroalbuminuric patients is primarily serum-derived and not locally produced.
1. Introduction
Diabetic nephropathy (DN) is considered to be one of the
most devastating microvascular complications of diabetes
mellitus (DM), developing in nearly one-third of patients
with type 1 or type 2 diabetes [1]. It is by far the most com-
mon cause of chronic kidney disease (CKD) worldwide, fre-
quently leading to end-stage renal disease (ESRD) and the
need for renal replacement therapy [2]. The combination of
ESRD and diabetes also imparts a hugely increased risk of
cardiovascular events [3, 4] and mortality [5].
DN typically develops through sequential phases, starting
with hyperfiltration, followed by the onset of albuminuria
and progressive decline in the glomerular filtration rate
(GFR) [6, 7]. Both eGFR and albuminuria are independent
risk factors for mortality and progression to ESRD and dis-
play a strong synergy in increasing risk [8]. There is compel-
ling evidence indicating that susceptibility to developing DN
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is, at least in part, genetically determined [9]. Amongst the
reported susceptibility loci, we have repeatedly reported in
the last decade on genetic variants of the CNDP1 gene that
are associated with serum carnosinase-1 (CN-1) levels and
the development of DN.
CN-1 is encoded by the CNDP1 gene, which harbours a
trinucleotide length (CTG)n polymorphism in the signal pep-
tide of CN-1 that influences secretion of the CN-1 protein
[10]. We and others have demonstrated that the CNDP1
(CTG)n polymorphism is associated with susceptibility to
developing DN in T2DM [11–15]. The shortest allelic form,
i.e., the CNDP1 (CTG)5 or Mannheim allele, is more com-
mon in the absence of nephropathy and is associated with
low CN-1 enzymatic activities and low serum concentrations
[10, 11, 16]. Nonetheless, it should also be mentioned that
other studies failed to demonstrate this association in cohorts
of different ethnicities [17, 18]. In patients with type 1 diabe-
tes, there are also inconsistent findings related to the associa-
tion between CNDP1 and ESRD. While in a genome-wide
SNP genotyping approach in 1,906 unrelated Caucasian indi-
viduals with type 1 diabetes, an association between ESRD
and CNDP1 was observed [19], this was not found in another
case-control study, consisting of 1,269 Caucasian patients
with type 1 diabetes [20]. Likewise, Alkhalaf et al. did not find
an association between the homozygous CNDP1 (CTG)5
genotype and DN in patients with type 1 diabetes but rather
an increased risk of progression to ESRD late after baseline
measurements [21].
The influence of the CNDP1 Mannheim allele has also
been investigated in nondiabetic nephropathies, where it
was found to be associated with a slower progression to
CKD and to correlate with renal survival in patients with
glomerulopathies, but not in patients with tubulointerstitial
disease [22, 23]. Notwithstanding the foregoing, there is
compelling evidence that carnosine, a major substrate of
CN-1, has renoprotective properties in animal models of dia-
betes [24–27]. Likewise, in human studies in patients with
T2DM, carnosine supplementation has been shown to have
a beneficial effect on hyperglycaemia [28, 29], triglycerides,
and inflammatory mediators [29].
The recent finding that the human kidney possesses an
intrinsic carnosine metabolism [30] and that CN-1 is detect-
able in urine of healthy subjects and patients with T2DM [31]
underscores its biological relevance in the context of kidney
disease. While initial studies have shown an increased
expression of CN-1 in biopsies of patients with DN [11,
30], we more recently demonstrated that CN-1 concentra-
tions in 24 h urine samples are increased in patients with
T2DM and macroalbuminuria and that this correlates with
urinary albumin excretion and renal function [31]. Although
24 h urine collection has been considered to be the gold stan-
dard for the assessment of albuminuria, specimens of the first
void or spot urine rather than 24h urine are more commonly
collected in biorepositories of patients with CKD.
Spot urine however is liable to hourly variations in uri-
nary protein and creatinine excretion and therefore may
deviate from 24h urine ACR assessment. Hence, to confirm
our previous findings in larger cohorts where 24 h urine col-
lections were available, the present study was conducted as a
proof of principle and sought to assess the relation between
CN-1 in spot urine, ACR, and renal function and to replicate
our earlier findings with 24 h urine collections. In essence, the
current study addressed (1) whether CN-1 can be reliably
measured in spot urine, (2) whether there is an association
between urinary CN-1, eGFR, and albuminuria in diabetic
and nondiabetic patients with chronic kidney disease, (3)
whether high urinary CN-1 concentrations in macroalbumi-
nuric patients are associated with low CN-1 concentrations
in serum, and (4) whether the (CTG)n polymorphism
known to determine CN-1 secretion is associated with uri-
nary CN-1 concentrations.
2. Materials and Methods
2.1. Participants and Sampling
2.1.1. Participants. A total of 111 patients (i.e., patients with
T2DM and chronic kidney disease (n = 85) and nondiabetic
patients with other causes of CKD (n = 26)) were included
in this study and stratified on the basis of the albumin/crea-
tinine ratio (ACR) in macroalbuminuria (ACR > 300mg/g)
and micro- or normoalbuminuria (ACR ≤ 300mg/g) groups.
For patient allocation, at least 2 independent assessments
with persistent ACR findings were required. Demographic
and clinical characteristics of the groups are presented in
Table 1.
Diabetes mellitus was defined by a documented history of
diabetes or a fasting blood glucose ≥ 7:0mmol/l (126mg/dl),
a casual plasma glucose level ≥ 11:1mmol/l (200mg/dl), or
HbA1c ≥ 6:5% (48mmol/mol). Nondiabetic patients with
CKD were included after screening of patient medical
records, medications, and laboratory testing for plasma glu-
cose or HbA1c to exclude diabetes.
Parameters including glycated hemoglobin (HbA1c),
body mass index (BMI), serum creatinine, and albuminuria/-
creatinine ratio (ACR) were extracted from medical records.
The estimated glomerular filtration rate (eGFR) was calcu-
lated according to the CKD-EPI formula. Patients that under-
went kidney transplantation or patients without residual
diuresis were excluded. Subjects withmissing urine and blood
sampling were also excluded. The study was approved by the
local ethics committee, and all patients gave written informed
consent prior to the study enrolment (no. 0193/2001). The
healthy controls consisted of 24 adults (16 females and 8
males) recruited from our laboratory staff that voluntarily
decided to participate, and all gave written informed consent
to study enrolment. Healthy controls had no history of diabe-
tes and cardiovascular or kidney disease.
2.1.2. Sampling. Serum and spot urine samples were collected
to assess CN-1 concentration. Genotyping was performed on
EDTA blood. All samples were stored at −20°C until use.
2.2. CNDP1 Genotyping. Genomic DNA was isolated from
EDTA blood using the Genomic DNA Isolation Kit (Pro-
mega, Mannheim, Germany). Thereafter, a standard PCR
protocol was used with the fluorescence-labeled forward
primer 5′-FAM-GCGGGGAGGGTGAGGAGAAC-3′ and
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the unlabeled reverse primer 5′GGTAACAGACCTTCTT
GAGGAATTTGG-3. After PCR amplification, fragment
analysis was performed with an ABI310 analyzer (PerkinEl-
mer) to determine the fragment length corresponding to
the different genotypes. Each peak corresponded with the
number of leucine repeats on each allele. The 157, 160, and
163 bp products corresponded with the (CTG)5, (CTG)6,
and (CTG)7 alleles encoding for five, six, and seven leucine
repeats, respectively.
2.3. Serum and Urinary CN-1 Concentrations. CN-1 concen-
trations in serum and urine weremeasured by ELISA as previ-
ously described by Adelmann et al. [32] and Rodriguez-Niño
et al. [31], respectively. In brief, high-absorbent microtiter
plates (Greiner, Labortechnik, Frickenhausen, Germany)
were coated overnight with 100μl of goat polyclonal anti-
human CN-1 (10μg/ml) (R&D, Wiesbaden, Germany). The
plates were extensively washed and incubated with 0.05% of
dry milk powder to avoid unspecific binding. Serum samples
were tested in a dilution of 1 : 100 or 1 : 200, and urine sam-
ples were tested undiluted. The plates were placed on a
shaker for 1 hour and subsequently extensively washed with
1x PBS/Tween. Thereafter, a rabbit polyclonal antibody
(ATLAS, Abcam plc, Cambridge, United Kingdom) was
added for 1 hour followed by extensive washing. A goat
anti-rabbit IgG HRP-conjugated antibody was added for
30min followed by extensive washing. Deep-blue peroxidase
(POD) (Roche Diagnostics, Mannheim, Germany) was used
for color development which was stopped after 20min by
the addition of 50μl of 1M H2SO4. The plates were directly
read at 450 nm fluorescence. A serial dilution of pooled
serum with a known carnosinase concentration (2μg/μl)
was used as the standard. CN-1 protein concentrations were
assessed in the linear part of the dilution curve with a lower
detection limit of 31 ng/ml. Concentrations below the detec-
tion limit were set at 31 ng/ml.
2.4. Statistical Analysis. Quantitative data were expressed as
means ± SD or SEM or median with the corresponding inter-
quartile range (IQR). For comparison of the groups, indepen-
dent Student’s t-test was applied for data with normal
distribution or the Mann-Whitney U or Kruskal-Wallis test
for data with nonnormal distribution. Qualitative data were
expressed as numbers and percentages and analyzed using
the χ2 test or Fisher exact test with Bonferroni correction
when appropriate. The correlations between urinary CN-1
and other parameters were analyzed by the Pearson or Spear-
man correlation analysis. Due to a skewed distribution, uri-
nary CN-1 concentrations were logarithmically transformed
together with the variables ACR and serum CN-1: log10 (uri-
nary CN-1), log10 (ACR), and log10 (serum CN-1). Variables
with a p value < 0.25 in the univariate analysis were included
in the multivariate model. Multivariate regression analysis
was employed with log-transformed urinary CN-1 as the
dependent variable to determine the best multivariate model
predicting urinary CN-1 concentrations. The association of
serum CN-1 (log10-transformed serum CN-1) with kidney
disease was analyzed with linear regression analysis with
adjustment for age and sex (model 1) and urinary CN-1
(model 2). All statistical tests were two-sided, and a p value
< 0.05 was considered statistically significant in all analyses.
The analyses were assessed with GraphPad Prism 7.02
(GraphPad Software, Inc., La Jolla, California) and SPSS
23.0 software (SPSS, Inc., Chicago, IL).
3. Results
3.1. Demographic and Clinical Characteristics. CN-1 concen-
trations in serum and in spot urine as well as the CNDP1
genotype were assessed in patients with T2DM (n = 85), in
patients with CKD but no diabetes (n = 26), and in healthy
controls (n = 24). T2DM patients were further stratified on
the basis of ACR into patients with normo- or microalbumi-
nuria (ACR ≤ 300mg/g) (n = 44) and patients with macroal-
buminuria (ACR > 300mg/g) (n = 41). Likewise, patients
with nondiabetic CKD were stratified into the same groups
(ACR ≤ 300mg/g) (n = 9) (ACR > 300mg/g) (n = 17).
Importantly, in the overall patient cohort (n = 111), only
18% (20 of 111) of the patients had normoalbuminuria
(ACR < 30mg/g) and less than 14% (16 of 111) of the
patients showed an eGFR above 60ml/min/1.73m2 reflecting
a population with predominantly severe renal function
impairment. Although 41% of all patients (46 of 111) were
on renal replacement therapy (hemodialysis or peritoneal
dialysis), all had residual urine output.
All relevant demographic and clinical characteristics of
the groups are depicted in Table 1. The healthy control group
consisted of adults without clinical signs or medical history of
renal disease or diabetes. In the control group, there were
more females included and the mean age was significantly
lower as compared to both disease groups (p < 0:0001). No
differences in this respect were observed between the
T2DM and CKD groups as a whole or between the ACR sub-
groups of T2DM and CKD, respectively. As expected, T2DM
patients withACR > 300mg/g displayed more frequently ret-
inopathy and had higher serum creatinine levels and lower
eGFR compared to T2DM patients with ACR ≤ 300mg/g.
Macroalbuminuric patients in the CKD group displayed
trends for increased serum creatinine and lower eGFR in
comparison to CKD patients with normo- or microalbumi-
nuria, but these differences did not reach statistical signifi-
cance. The main causes of CKD of nondiabetic aetiology
were IgA nephropathy, focal glomerular sclerosis, and other
glomerulonephritides.
3.2. Urinary CN-1 Concentrations Are Increased in Patients
with Macroalbuminuria. In the group of patients with
T2DM and macroalbuminuria, CN-1 was detected in 95%
(39 of 41) of the urine samples while in those with normo-
and microalbuminuria, only 48% (22 of 44) of urine samples
were positive for CN-1 (p < 0:0001). Likewise, CN-1 was
detected in 88% of urine samples (15 of 17) from patients
with nondiabetic CKD and macroalbuminuria as compared
to 33% (3 of 9) of urine samples from patients with normo-
and microalbuminuria (p = 0:007) (Table 1). Median urinary
CN-1 concentrations in patients with T2DM and macroal-
buminuria were significantly higher in comparison to those
in T2DM patients with normo- and microalbuminuria
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(554 ng/ml [IQR 212-934ng/ml] vs. 31 ng/ml [IQR 31-
64 ng/ml], ACR > 300 vs. ACR ≤ 300mg/g; p < 0:0001). This
was also true for the nondiabetic CKD group (197 ng/ml
[IQR 112-739] vs. 31 ng/ml [IQR 31-226 ng/ml], ACR >
300 vs. ACR ≤ 300mg/g; p = 0:016) (Figure 1(a)).
Of note, the median urinary CN-1 concentrations of
healthy individuals were significantly lower compared to
those of T2DM patients with macroalbuminuria (p < 0:0001
), and healthy individuals showed with borderline signifi-
cance lower urinary CN-1 concentrations compared to the
nondiabetic group with macroalbuminuria (p = 0:05) (data
not shown).
In the overall population of patients (n = 111), a positive
correlation between urinary CN-1 and ACR was found
(r = 0:68, p < 0:0001) (Figure 1(b)). Patients with reduced
renal function (eGFR < 60ml/min/1:73m2) were found to
have significantly higher urinary CN-1 concentrations com-
pared to patients with preserved renal function (eGFR > 60
ml/min/1:73m2) (p = 0:015) (Figure 1(c)). When three
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Figure 1: (a) Distribution of CN-1 in spot urine of T2DM and nondiabetic patients (CKD) with normo- or microalbuminuria
(ACR ≤ 300mg/g) and macroalbuminuria (ACR > 300mg/g). Results for each individual patient are shown as well as the median and IQR
(lines) for each of the different groups. (b) Pearson correlation between ACR [log (ACR)] and urinary CN-1 concentrations [log (urinary
CN-1)] in patients with T2DM and nondiabetic CKD patients (n = 111). (c) Distribution of urinary CN-1 concentrations in all patients
according to eGFR. T2DM and CKD patients (n = 111) were stratified according to reduced (eGFR < 60ml/min/1:73m2) (n = 95) and
preserved renal function (eGFR > 60ml/min/1:73m2) (n = 16). eGFR was estimated using the CKD-EPI formula. Boxes and whiskers
represent the median and IQR. Outliers are indicated by circles.
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were applied, urinary CN-1 concentrations differed
between eGFR < 30ml/min and >60ml/min with border-
line significance (p = 0:056) (data not shown).
3.3. Serum CN-1 Concentrations in T2DM and Nondiabetic
CKD Patients and Healthy Individuals. Based on the findings
that urinary CN-1 concentrations are increased in patients
with macroalbuminuria regardless of the underlying renal
disease and because our previous studies suggested low
serum CN-1 concentrations to be present in T2DM patients
with impaired renal function [33], we assessed if high urinary
CN-1 concentrations were associated with decreased CN-1
levels in serum.
To test this, all patients were stratified on the basis of ACR
in normo-, micro-, and macroalbuminuria (ACR < 30, 30-
300, and >300mg/g, respectively). As shown in Figure 2(a),
there were no significant differences in serum CN-1 concen-
trations amongst these 3 groups. Serum CN-1 levels did not
differ between patients with impaired and patients with
preserved renal function (4.0μg/ml [IQR 2.5-10.53μg/ml]
vs. 2.8μg/ml [IQR 0.97-10.43μg/ml]) for eGFR < 60 and
eGFR > 60ml/min/1:73m2, respectively (p = 0:25). Likewise,
serum CN-1 concentrations were not different between
patients with poor, moderate, or preserved renal function
(Figure 2(b)), albeit the mean serum CN-1 concentration
in patients with eGFR < 30 was the lowest (8:66 ± 1:33 vs.
all other eGFR strata, p > 0:05). A weak but significant pos-
itive correlation between serum and urinary CN-1 concen-
trations was observed for the whole cohort of patients
(n = 111) (r = 0:22, p = 0:02) (Figure 2(c)).
When patients were compared to the healthy group,
serum CN-1 concentrations were significantly higher in
healthy controls (9.4μg/ml [IQR 4.8-24.8μg/ml] vs.
4.1μg/ml [IQR 2.1-10.5μg/ml], p = 0:0013) (Figure 2(d)).
This could not be explained by differences in genotype
distribution of the homozygous CNDP1 (CTG)5 genotype
(Figure 2(e)) (p = 0:9), which is associated with low serum
CN-1 levels, but may be related to the higher proportion of
females included in the healthy control group (67% in the
healthy vs. 35% in the disease group) (p = 0:0055).
The finding of low serum CN-1 levels in kidney disease
patients was further investigated to control for potential con-
founders. Serum CN-1 concentration was set as the depen-
dent variable, and a linear regression analysis including all
participants (healthy subjects and kidney disease patients)
(n = 128) was performed. In the crude model, the status of
kidney disease patients was inversely correlated with low
serum CN-1 concentrations (β = −0:258, p = 0:003). After
adjustment for sex and age, the association of the kidney dis-
ease patient and serum CN-1 slightly weakened and was no
longer significant (β = −0:219, p = 0:089) (model 1), but the
association became uncovered again by further adjustment
for urinary CN-1 concentrations (β = −0:281, p = 0:033)
(model 2) (Supplementary Table 1).
In line with this finding, higher urinary CN-1 concentra-
tions were observed in all the kidney disease patients versus
healthy subjects (143.7 ng/ml [IQR 31-619.6 ng/ml] vs.
79.13 ng/ml [IQR 31.7-121.7 ng/ml], p = 0:027; Figure 2(f)).
3.4. Influence of the CNDP1 Genotype on Serum and Urinary
CN-1 Concentrations. We first assessed in healthy subjects if
the homozygous CNDP1 (CTG)5 genotype was associated
with low serum and urinary CN-1 concentrations. Serum
CN-1 concentrations were approximately 100-fold higher
as compared to those found in spot urine (serum CN-1:
median 9.4μg/ml [IQR 4.8-24.2μg/ml]; urinary CN-1:
median 79 ng/ml [IQR 32-122 ng/ml]) (Figure 3(a)). While
in serum CNDP1 (CTG)5 homozygous individuals displayed
significantly lower CN-1 concentrations as compared to
all other genotypes (5.5μg/ml [IQR 3.2–9.1μg/ml] vs.
11.7μg/ml [IQR 5.5-33.3μg/ml], p = 0:019), this was not
found for urinary CN-1 concentrations (81.3 ng/ml [IQR
31-146 ng/ml] vs. 77 ng/ml [IQR 33-118.5 ng/ml], p = 0:94)
(Figure 3(a)). Neither in serum nor in urine of T2DM
patients, differences in CN-1 concentrations were found
between CNDP1 (CTG)5 homozygous individuals and indi-
viduals carrying a different genotype (>CTG)5 (in serum:
3.5μg/ml [IQR 1.9-10.9] versus 4.4μg/ml [IQR 2.6-12.7]
(p = 0:62) and in urine: 60 ng/ml [IQR 31-503.2] vs.
141.3 ng/ml [IQR 34.1-718.5] (p = 0:14)) (Figure 3(b)).
3.5. Serum CN-1 Concentrations and Albuminuria Are the
Main Predictors of Urinary CN-1 in T2DM and Nondiabetic
CKD Patients. To assess factors predicting urinary CN-1
concentrations, relevant kidney disease-associated variables,
i.e., age, gender, baseline kidney disease (diabetic or nondia-
betic CKD), renal replacement therapy, serum CN-1 concen-
trations, (CTG)5 homozygosity, eGFR, ACR, and residual
diuresis, were selected as independent predictors of log-
transformed urinary CN-1 concentrations [log (urinary
CN-1 concentration)] (Table 2). In univariate analysis, the
variables baseline kidney disease, renal replacement therapy,
and residual diuresis did not reach the significance threshold
of p < 0:25 and were excluded in the multivariate linear
regression model (Table 2). ACR and serum CN-1 concen-
trations were found to be the strongest predictors of uri-
nary CN-1 concentrations, all together explaining 47% of
variation of log (urinary CN-1 concentration) (R2 = 0:47,
p < 0:0001).
4. Discussion
Proteinuria, routinely assessed in patients with chronic kid-
ney disease (CKD), is a well-established biomarker for the
progression of renal function deterioration in patients with
or without diabetes [34]. Assessment of proteinuria based
on 24 h urine collection was previously considered the gold
standard. Yet because of its inconvenience and collection
inaccuracies [35, 36] in recent years, clinical practice guide-
lines [37] suggest the first void or spot urine albumin-to-
creatinine ratio (ACR) to assess progression of CKD and
treatment evaluation. As such, specimens of the first void
or spot urine rather than 24 h urine are mostly collected in
biorepositories of patients with CKD. Nonetheless, it should
be emphasized that spot urine collections are liable to hourly
variations in urinary protein and creatinine excretion and
therefore may not match ACR if it had been determined
based on a 24 h collection.
6 Journal of Diabetes Research





























































































































Figure 2: (a) Distribution of serumCN-1 concentrations in all the studied patients (n = 111) according to ACR in normoalbuminuria (n = 20),
microalbuminuria (n = 33), and macroalbuminuria (n = 58). Boxes and whiskers represent the median and IQR. (b) According to eGFR in
severely decreased (n = 72), mildly decreased (n = 23), and preserved eGFR (n = 16). (c) Spearman correlation of serumCN-1 [log (serumCN-1])
and urinary CN-1 [log (urinary CN-1)] concentrations in all patients (n = 111). (d) Patients (n = 104) display lower serum CN-1 concentrations
in comparison to healthy subjects (n = 24). (e) Differences are not related to the distribution of the homozygous CNDP1 (CTG)5 versus all
other genotypes (>CTG)5 (p = ns). (f) Patients (n = 104) have higher urinary CN-1 levels compared to the healthy group (n = 24).
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We have previously reported that CN-1 in 24h urine of
patients with T2DM is associated with renal function
impairment and urinary albumin excretion rate [31]. In
order to confirm these findings in larger cohorts where only
spot urine is available, the present study was conducted as a
feasibility study in a smaller group of CKD patients to assess
the relation between CN-1 in spot urine, ACR, and renal
function. Additionally, we tested the influence of serum
CN-1 concentrations and the CNDP1 genotype on urinary
CN-1 expression. The main findings of our study are the fol-
lowing: Firstly, urinary CN-1 is more frequently detected
and displays higher concentrations in patients with macroal-
buminuria as compared to those with normo- or microalbu-
minuria. Secondly, a strong positive correlation between
urinary CN-1 and ACR was found (r = 0:68, p < 0:0001).
Thirdly, patients with severely to moderately impaired
renal function (eGFR < 60ml/min/1:73m2) displayed higher
urinary CN-1 concentrations compared to patients with
preserved renal function (147.5 vs. 33 ng/ml, p = 0:015).
Fourthly, ACR and serum CN-1 concentrations are indepen-
dent predictors of urinary CN-1, explaining together 47% of
variation of urinary CN-1 concentrations (R2 = 0:47, p <
0:0001). These data are concordant with our previous results
using 24 h urine samples and thus suggest that spot urine can
be used for the assessment of CN-1 in biorepositories in
which spot rather than 24 h urine samples were collected.
Based on the previous observation that T2DM patients
with poor renal functionhave low serumCN-1 concentrations
[33], we hypothesized that high urinary CN-1 concentrations
in patients with poor renal function and albuminuria might
be associated with low CN-1 concentrations in serum as a
result of an impaired glomerular barrier. Although in the
current study, mean serum CN-1 concentration in patients
with poor renal function was numerically lower compared
to that in patients with moderately impaired or preserved
renal function, this did not reach statistical significance. It
should be underscored however that in our previous study,
only patients with T2DM were included of which 127 were
assigned as having DN and 76% hereof were on renal replace-
ment therapy [33]. This is in sharp contrast to the present
study where only 85 patients with T2DM were included of
which 38% required dialysis.
Because urinary CN-1 excretion is much higher in
patients with impaired renal function but serum concentra-
tions are not that much different, we presume that the total
production of CN-1 goes up to compensate for losses,
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Figure 3: Distribution of serum CN-1 (left y-axis) and urinary CN-1 concentrations (right y-axis) according to the CNDP1 (CTG)5
homozygous genotype versus other CNDP1 genotypes (>CTG)5 in healthy subjects (n = 24) (a) and in patients with T2DM (n = 85) (b).
Results are expressed for each individual patient. The lines represent the median and IQR. Note that the units on the left and right y-axes
are expressed in μg/ml and ng/ml, respectively.
Table 2: Summary of univariate and multivariate regression analyses predicting urinary CN-1 concentrations in T2DM and nondiabetic
CKD patients (n = 104).
Univariate analysis Multivariate analysis
Variable Coefficient (β) 95% CI p value Coefficient (β) 95% CI p value
Age (years) -0.007 -0.014 0.001 0.092 0.002 -0.005 0.010 0.56
Male sex 0.17 -0.08 0.42 0.18 0.14 -0.044 0.33 0.13
Nondiabetic kidney disease 0.075 -0.208 0.36 0.60 — — —
On renal replacement therapy -0.095 -0.34 0.15 0.43 — — —
CNDP1 (CTG)5 homozygosity -0.500 -0.43 0.08 0.17 -0.033 -0.23 0.16 0.74
Log (serum CN-1) 0.195 -0.012 0.40 0.065 0.21 0.053 0.36 0.009
Log (ACR) 0.47 0.37 0.57 <0.0001 0.48 0.37 0.60 <0.0001
eGFR (ml/min/1.73m2) -0.009 -0.009 -0.0004 0.032 0.001 -0.003 0.005 0.66
Univariate and multivariate regression models with log-transformed urinary CN-1 as the dependent variable. Goodness of fit of the multivariate regression full
model: adjusted R2 = 0:47; p < 0:0001.
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resulting in relatively similar serum concentrations despite
the losses that occur into urine.
Nonetheless, the strong correlation between urinary CN-
1 concentrations and albuminuria suggests that increasing
CN-1 concentrations likely reflects impairment of the glo-
merular filtration barrier. This may also partly explain the
positive correlation between serum CN-1 and urinary CN-1
concentrations in patients (Figure 2(c)) but not in healthy
controls (data not shown), as in patients with an impaired
glomerular filtration barrier, such a correlation would be
expected. In line with this, in the multivariate regression
model, serum CN-1 concentration was identified as an inde-
pendent predictor of urinary CN-1 concentrations. Likewise,
positive correlations between albumin synthesis and urinary
albumin excretion have been reported in patients with
macroalbuminuria [38].
Of note, high serum CN-1 concentrations were observed
in the healthy subjects in comparison to the disease group
(Figure 2(f)). Although it appeared that age and sex were
influencing these differences, the uncovering effect by the
addition of urinary CN-1 suggests that the association of kid-
ney disease and low serum CN-1 concentrations is linked to
urinary CN-1 concentrations (Supplementary Table 1).
These observations support the assumption that serum
CN-1 is lost into urine in patients with kidney disease,
already in early stages of the disease, probably due to glomer-
ular leakage or poor tubular reabsorption or a combination of
both. In patients with kidney disease, serum CN-1 is replen-
ished but not to physiological levels (Figure 2(d)).
Together, our findings reveal that serum CN-1 and uri-
nary CN-1 under healthy and kidney disease conditions
might follow opposite patterns: whereas healthy subjects
have higher levels of serum CN-1 in comparison to kidney
disease patients (Figure 2(d)), kidney disease patients excrete
higher amounts of urinary CN-1 in comparison to the
healthy individuals (Figure 2(f)).
Due to reduced diuresis and increased prevalence of pro-
tein energy wasting, correlations between serum and urinary
CN-1 concentration might become blurred as renal function
deterioration progresses. Additionally, low serum CN-1 con-
centrations have indeed been reported in pathologies charac-
terized by a high catabolic state, e.g., neoplasia and liver
cirrhosis [39–41], making protein energy wasting a likely
factor influencing serum CN-1 concentrations in patients
with low residual renal function. Alternatively, dialysis per
se and metabolic acidosis, a common comorbidity of CKD,
can promote enhanced protein breakdown and amino acid
oxidation [42, 43].
Although renal CN-1 mRNA and protein expression has
been reported [11, 13, 30], to the best of our knowledge, there
are no studies that provide direct evidence for renal CN-1
secretion into the renal tubular lumen. Yet the lack of corre-
lation between serum and urinary CN-1 concentrations in
healthy individuals argues against CN-1 filtration and a free
communication between the circulatory and urinary com-
partments and tempted us to presume that urinary CN-1 is
a consequence of renal production and secretion. Nonethe-
less, it cannot be excluded that serum CN-1 partly exists in
a monomeric conformation [44] and, based on a similar
molecular weight and isoelectric point as albumin, might
pass the filtration barrier.
It is also worthwhile to mention that in contrast to serum
CN-1 concentrations, urinary CN-1 concentrations were not
influenced by the CNDP1 (CTG)n polymorphism. Since it
has been shown that variations in the leucine repeat in the
signal peptide of CN-1 affect CN-1 secretion [10], this would
also be expected for renal CN-1 secretion. If however mono-
meric serum CN-1 is filtered, urinary CN-1 concentrations
will correlate more with the fraction of monomeric CN-1
rather than the CNDP1 genotype. Our in-house ELISA used
for CN-1 detection cannot distinguish between CN-1 mono-
mers and dimers, and the small amount of CN-1 as well as
the presence of urea in the urine sample of healthy controls
also hampers drawing firm conclusions from Western blot-
ting experiments.
Although patients with low eGFR appeared to have higher
urinary CN-1 concentrations compared to patients with pre-
served renal function (eGFR > 60ml/min/1:73m2) and the uni-
variate analysis revealed a significant negative correlation
between eGFR and urinary CN-1, the subsequent multivariate
regressionmodel excluded eGFR as an independent explanatory
factor for urinary CN-1. This could be explained by the follow-
ing: (1) The currently studied population has considerable renal
function impairment compared to our previous study. Thus, it
might be that at late stages of the disease, eGFR influences
urinary CN-1 concentrations to a lesser extent; (2) a possible
collinearity between the variables eGFR and ACRmay add sim-
ilar information, and thus, only the variable with the strongest
relationship is included in the final model [45]. Based on the lat-
ter, it can be concluded that for the group of patients, ACR is a
stronger predictor of urinary CN-1 concentrations than eGFR.
Noteworthy, the correlation coefficient between urinary CN-1
and albuminuria (ACR) in spot urine was higher, and the good-
ness of fit was even better than the one previously reported in the
24h urine study (r = 0:68 and R2 = 0:47, p < 0:0001) versus
(r = 0:59 and R2 = 0:37, p < 0:0001) [31].
The confirmation and reproducibility of the findings
from the 24 h urine study in the present data suggest that
the assessment of CN-1 in spot samples may be considered
similarly reliable as in 24h samples. This has already been
suggested for the assessment of proteinuria [46]. Multivariate
linear regression analysis revealed that albuminuria (ACR)
and serum CN-1 can be considered independent predictors
of urinary CN-1 in nondiabetic and diabetic patients with
CKD. If we speculate that in this group of patients, the major-
ity of detected CN-1 in urine originates from the circulation,
these findings might imply that the concentration of CN-1 in
urine is a function of two independent processes: on the one
hand changes in glomerular permselectivity reflected by a
strong positive correlation with albuminuria and on the other
hand the ability of the liver to maintain CN-1 production.
Apart from the finding that urinary CN-1 likely reflects
impairment of the glomerular filtration barrier, we propose
that the additional value of urinary CN-1 as a potential bio-
marker resides in its enzymatic properties. Because the
major CN-1 substrates carnosine and anserine are endowed
with antioxidative and antiglycating properties, they may
prevent/reduce oxidative or glycative tissue damage. If high
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urinary CN-1 is associated with low renal levels of these
histidine-containing dipeptides (HCD), this may mirror the
ability of the kidney to protect itself against noxious reactive
oxygen or carbonyl species. The relation between high renal
CN-1 activity and low renal HCD levels has been demon-
strated in diabetic mice. CN-1 activity is increased by CN-1
carbonylation and possibly also by oxidative stress as indi-
cated by the studies of Peters et al. and Bellia et al. [47–49].
4.1. Limitations of the Study. Even though the current study is
in concordance with our previously published data, there are
some limitations that need to be addressed. Firstly, the num-
ber of healthy controls is relatively small and healthy controls
were not matched for gender and age with the patient cohort.
Hence, conclusions based on any direct comparisons
between patients and controls cannot be firmly drawn and
should be taken with caution. Secondly, it would be useful
to directly compare 24 h urine and spot urine of the same
individual. We are aware that this would have been the most
ideal situation; however, at the time of the study, 24 h urine
samples were not available for most of the patients. The
intention of this study was to assess the feasibility of mean-
ingful measurement of urinary CN-1 concentrations in spot
urine. Further epidemiological studies with a prospective
design are warranted for evaluating the sensitivity, specificity,
negative and positive predictive values of urinary CN-1 for
CKD progression and decline in GFR.
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